September 5, 2026

Dear Providers and Medical Office Teams,

Nationwide Compounding Rx can no longer supply compounded medications as general office stock. Moving forward, we will require a valid patient-specific prescription for every medication we dispense, including nonsterile preparations such as BLT topical anesthetic creams and ointments.

Arizona’s amended compounding rule became effective September 5, 2026. The former R4-23-410(B)(3) allowed provision of compounded products to medical practitioners for administration with specific office-use labeling. The revised rule replaces that provision with an exception limited to veterinary practitioners. There is no corresponding exception for nonsterile human office stock. [1, 2]

Under R4-23-410(E), medication prepared in anticipation of prescriptions must be held until dispensed under a patient-specific prescription, except for the veterinary provision in subsection (F). Preparing a batch in advance does not authorize supplying it to a medical office for use across unidentified patients. Labeling a product “For Office Administration Only” does not satisfy the new requirement. [1]

For future orders, please:

• Submit a separate valid prescription for each patient, including the patient’s full name, date of birth, medication, strength, dosage form, quantity, directions, and required prescriber information.
• Send prescriptions electronically or by fax to (480) 699-5341. Call (480) 499-8379 for assistance or verbal orders where permitted. Our website inquiry form cannot be used to submit prescriptions.
• Place orders before scheduled procedures and allow time for processing and compounding. Medication dispensed for one patient must remain designated for that patient and cannot serve as shared office stock.

Offices that need non-patient-specific compounded stock may contact an appropriately licensed, FDA-registered 503B outsourcing facility. FDA guidance identifies this pathway for both sterile and nonsterile office-use preparations, subject to applicable requirements. [3]

Please contact our pharmacy team with questions or for assistance transitioning your orders. Thank you for working with us to support your patients and meet these requirements.

Sincerely,

Austin Lucht, Pharm.D., MBA

Director of Pharmacy

[1] A.A.C. R4-23-410(E)–(F), current rule, pp. 29–30.

[2] Arizona Board of Pharmacy, final rulemaking effective September 5, 2026.

[3] FDA, Prescription Requirement Under Section 503A (December 2016), §§ III.C–D.